新冠檢測板塊拉昇 熱景生物(688068.SH)漲超13%
格隆匯11月23日丨熱景生物漲超13%,東方生物、透景生命、碩世生物、邁克生物等跟漲。消息面上,近日,熱景生物新冠抗原檢測產品獲得烏克蘭醫用註冊批准,截至目前該產品已獲得新加坡、祕魯、馬來西亞、肯尼亞、土耳其以及歐盟CE註冊認證。此外,熱景生物新冠抗原自測產品繼獲得德國BfArM、英國MHRA、泰國TFDA註冊批准後,又獲得文萊自測使用註冊批准。近期歐美疫情再度惡化,為控制疫情蔓延,多國加緊防疫政策,鼓勵居家自測新冠。此前,熱景生物新冠自測試劑已成為德國市場主流自測產品,隨着德國第四波疫情反彈,自測市場需求大增,多地商超、藥店出現搶購一空的現象。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.